ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Clinical trial NCT03698552 · TERMINATED

Trial details

NCT number: NCT03698552
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Blasts 5 Percent or More of Bone Marrow Nucleated Cells CD22 Positive Philadelphia Chromosome Positive Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia

Start date: 2018-08-24
Primary completion: 2025-11-06
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.